ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
46 hedge funds and large institutions have $58.8M invested in ESSA Pharma in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 10 closing their positions.
225% more call options, than puts
Call options by funds: $179K | Put options by funds: $55K
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
44% more funds holding
Funds holding: 32 → 46 (+14)
5.09% less ownership
Funds ownership: 79.11% → 74.03% (-5.1%)
72% less capital invested
Capital invested by funds: $213M → $58.8M (-$154M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$13.7M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$13.4M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$7.04M |
| 4 |
ACM
Altium Capital Management
New York
|
+$4.55M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$47.8M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$16.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.93M |
| 4 |
RI
RTW Investments
New York
|
-$6.84M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.45M |
EPIX Hedge Fund Activity: Q4 2024 in Review
46 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q4 2024, worth a combined $58.8M — down 72% from $213M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new EPIX positions and 10 closed out — a net gain of 14 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $13.7M. The largest seller was Bellevue Group, exiting entirely with an estimated $47.8M sold.
- 46 institutional investors held ESSA Pharma (EPIX) as of Q4 2024, up from 32 in Q3 2024.
- Funds reported $58.8M of ESSA Pharma stock for Q4 2024, down 72% quarter-over-quarter.
- 24 funds opened new ESSA Pharma positions in Q4 2024 and 10 closed out, a net change of +14 holders.
- The largest ESSA Pharma buyer in Q4 2024 was Tang Capital Management, an estimated $13.7M added.
- The largest ESSA Pharma seller in Q4 2024 was Bellevue Group, an estimated $47.8M sold.
Based on aggregated 13F filings for Q4 2024.